|本期目录/Table of Contents|

[1]王光宇,胡丹凤,李光宇,等.接种新型冠状病毒疫苗与感染奥密克戎变异株患者心肌损伤和预后的关系[J].国际心血管病杂志,2023,04:235-241.
　WANG GuangyuHU DanfengLI GuangyuHU FengZANG MinhuaPU Jun.Effect of COVID-19 vaccination on myocardial injury and prognosis in patients infected with Omicron variant[J].International Journal of Cardiovascular Disease,2023,04:235-241.
点击复制

接种新型冠状病毒疫苗与感染奥密克戎变异株患者心肌损伤和预后的关系(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2023年04期
页码:
235-241
栏目:
临床研究
出版日期:
2023-07-30

文章信息/Info

Title:
Effect of COVID-19 vaccination on myocardial injury and prognosis in patients infected with Omicron variant?
作者:
王光宇; 胡丹凤; 李光宇; 胡锋; 臧敏华; 卜军
200127 上海交通大学医学院附属仁济医院心内科通信作者：卜军，E-mail：pujun310@hotmail.com
Author(s):
WANG Guangyu; HU Danfeng; LI Guangyu; HU Feng; ZANG Minhua; PU Jun?
Department of Cardiology, School of Medicine, Renji Hospital, Shanghai Jiao TongUniversity, Shanghai 200127, China
关键词:
新型冠状病毒疫苗; 奥密克戎变异株; 心肌损伤; 预后
Keywords:
COVID-19 vaccine;  Omicron variant;  Myocardial injury;  Prognosis
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2023.04.011
文献标识码:
-
摘要:
目的：分析接种新型冠状病毒（新冠病毒）疫苗与奥密克戎（Omicron）变异株感染者心肌损伤和预后的关系。方法：回顾性分析2022年4月7日至2022年6月1日上海交通大学医学院附属仁济医院收治的450例Omicron变异株感染者。根据是否发生心肌损伤分为心肌损伤组和无心肌损伤组；根据预后分为死亡组和存活组。收集患者的人口学特征、流行病学、实验室检查资料、治疗措施、住院天数和预后情况。单因素和多因素logistic回归分析心肌损伤和死亡的相关危险因素。结果：心肌损伤组患者新冠病毒疫苗接种比例明显低于无心肌
Abstract:
Objective:To analyze the effect of COVID-19 vaccination on myocardial injury and prognosis in patients infected with Omicron variant.? Methods: A total of 450 patients infected with Omicron variant treated in Renji Hospital, School of Medicine, Shanghai J

参考文献/References

[1]WHO. Weekly operational update on COVID-19[EB/OL]. (2022-10-03)[2022-10-08]. http://www.covid.who.int/.
[2]Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial[J]. Lancet Infect Dis, 2021, 21(2):181-192.
[3] 胡明霞, 袁建明, 张彬, 等. 新型冠状病毒疫苗的研究进展[J]. 中国感染与化疗杂志, 2022, 22(4):504-508.
[4]Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2[J]. Science, 2020, 369(6499):77-81.
[5]Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes:interim analysis of 2 randomized clinical trials[J]. JAMA, 2020, 324(10):951-960.
[6]Johnson AG, Amin AB, Ali AR, et al. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence—25 U.S. jurisdictions, April 4-December 25, 2021[J]. MMWR Morb Mortal Wkly Rep,2022, 71(4):132-138.
[7] 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 中华临床感染病杂志, 2022, 15(2):81-89.
[8]Callaway E. Heavily mutated Omicron variant puts scientists on alert[J]. Nature, 2021, 600(7887):21.
[9] 孙丹, 杨金燕, 夏婷婷, 等. 新型冠状病毒Omicron变异株的流行病学特征及防控研究进展[J]. 中华医院感染学杂志, 2022, 32(8):1266-1270.
[10] Tian D, Sun Y, Xu H, et al. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant[J]. J Med Virol, 2022, 94(6):2376-2383.
[11] Collie S, Champion J, Moultrie H, et al. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa[J]. N Engl J Med, 2022, 386(5):494-496.
[12] Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity[J]. JAMA, 2021, 326(20):2043-2054.
[13] D'Andrea A, Russo V, Manzo G, et al. Association of atrial fibrillation and left atrial volume index with mortality in patients with COVID-19 pneumonia[J]. Eur J Prev Cardiol, 2022, 29(2):e44-e46.
[14] Song Y, Gao P, Ran T, et al. High inflammatory burden: a potential cause of myocardial injury in critically ill patients with COVID-19[J]. Front Cardiovasc Med, 2020, 7:128.
[15] Qian H, Gao P, Tian R, et al. Myocardial injury on admission as a risk in critically ill COVID-19 patients: a retrospective in-ICU study[J]. J Cardiothorac Vasc Anesth, 2021, 35(3):846-853.
[16] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2):271-280.
[17] Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2[J]. Circ Res, 2020, 126(10):1456-1474.
[18] 苏杭, 张霞, 段凤阳, 等. 接种新型冠状病毒灭活疫苗后感染Delta变异株的新型冠状病毒肺炎患儿临床特征分析[J]. 中国当代儿科杂志, 2022, 24(7):742-747.

备注/Memo

备注/Memo:
（收稿：2022-10-14 修回：2023-06-07）
更新日期/Last Update: 2023-08-01